Key Drivers
- Gross Margin
- Cash Burn
- Negative Equity
AIAI Summary
RARE is now better viewed as a commercial-stage rare-disease platform with real revenue growth, 84% gross margins, and near-term FDA/Phase 3 catalysts that could re-rate the stock, but the core risk is still a strained balance sheet and ongoing cash burn that make execution and financing discipline critical.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Gross Margin
- •Cash Burn
- •Negative Equity
RARE's 84% gross margin is strong, but persistent operating losses, heavy cash burn, weakening liquidity, and negative equity make the business look financially distressed despite solid product economics.
ക
Price Behavior
Key Price Behavior Insights:
- •Downtrend easing
- •Support holding
- •Breakout needed
RARE has been weak over the last month, but after holding $24.91-$25.00 support and recovering into the $26s, it now needs a decisive break above $27.0 to improve its near-term outlook.
Fell from $29.28 to $26.49 over the last month, then stabilized in the $26s after support held
Sentiment & News
Key News Insights:
- •Q2 Beat
- •FDA Catalysts
- •Profitability Path
Ultragenyx beat Q2 expectations with $214M revenue and a smaller loss, reaffirmed 2026 guidance, and heads into a catalyst-heavy second half with two PDUFA decisions and GTX-102 data likely driving sentiment.
Stronger-than-expected results and upcoming regulatory milestones likely support the stock, though volatility may remain elevated around key FDA decisions and clinical data
Similar Companies in Healthcare
Other companies in the same sector with AI ratings